Monitor for additional selling in the next 30 days and review upcoming Form 4s to determine if this is part of a broader trend. The small dollar size and timing with routine grants suggest limited significance, but continued selling could signal weakening confidence.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 17 $2.71entry
- T+1 · 8mo ago −7.38%α −5.98% · $2.51
- T+5 · 8mo ago −3.32%α −0.67% · $2.62
- T+20 · 7mo ago −19.93%α −24.23% · $2.17
- T+60 · 5mo ago +15.87%α +6.01% · $3.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple executives at Esperion Therapeutics, including the CEO, CFO, and Chief Legal Officer, sold shares in the open market totaling approximately $102,352 over the past week. These sales coincided with large non-cash stock award grants to the same insiders, a routine compensation event, suggesting the sales may be part of pre-arranged 10b5-1 plans or personal liquidity management rather than a signal of fundamental concerns.
Key Financial Metrics
Key Facts
- CEO Sheldon Koenig sold $69,547 worth of shares, representing the largest individual sale in the cluster.
- CFO Benjamin Halladay and Chief Legal Officer Benjamin Looker sold $17,377 and $15,429 worth of shares, respectively.
- All three executives received substantial non-cash stock awards on March 13, totaling over 1.8 million shares collectively, which is consistent with annual equity compensation practices.
- Total open-market sales in the cluster amount to $102,352, representing just 0.015% of the company's $696M market cap, well below the 0.1% threshold for materiality.
- No insider purchases were reported; all transactions were either sales or non-cash grants.
Financial Impact
$102,352 in open-market sales by executives, offset by $0 in economic value from stock awards (non-cash).
Risk Factors
- Perception risk: Concentrated selling by top executives, even if planned, may be interpreted negatively by the market.
- Dilution: The large stock awards (over 1.8M shares) will increase share count, potentially pressuring per-share metrics if not offset by growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-ESPR-1773864824503 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers